Consensus statement: Guidelines for PSA following radiation therapy

[1]  H M Sandler,et al.  Rate of PSA rise predicts metastatic versus local recurrence after definitive radiotherapy. , 1997, International journal of radiation oncology, biology, physics.

[2]  A Pollack,et al.  Prostate-specific antigen and radiation therapy for clinically localized prostate cancer. , 1995, International journal of radiation oncology, biology, physics.

[3]  A. Zietman,et al.  Use of PSA nadir to predict subsequent biochemical outcome following external beam radiation therapy for T1-2 adenocarcinoma of the prostate. , 1996, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[4]  A. Zietman,et al.  The effect of pelvic radiation therapy on serum levels of prostate specific antigen. , 1994, The Journal of urology.

[5]  A. Zietman,et al.  The treatment of prostate cancer by conventional radiation therapy: an analysis of long-term outcome. , 1995, International journal of radiation oncology, biology, physics.

[6]  D. Kuban,et al.  Prostate-specific antigen for pretreatment prediction and posttreatment evaluation of outcome after definitive irradiation for prostate cancer. , 1995, International journal of radiation oncology, biology, physics.

[7]  J R Anderson,et al.  Analysis of survival by tumor response. , 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  I. Kaplan,et al.  Prostate-specific antigen kinetics after external beam irradiation for carcinoma of the prostate. , 1994, International journal of radiation oncology, biology, physics.